Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer

NCT00555919 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00555919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00555919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
March 31, 2011
Enrollment
68 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer